This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

What is the purpose of this study?This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acuteyeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or byg them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is madeway that makes the drugs stay in the bone marrow longer and could be less likely touse heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gened FLT3. Genes are pieces of DNA (molecules that carry instructions for development,unctioning, growth and reproduction) inside each cell that tell the cell what to do and whengrow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out whichbetter, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapywith high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib withdard chemotherapy may work better in treating patients with acute myeloid leukemiad to standard chemotherapy alone. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

What is the purpose of this study?The purpose of this study is to collect and store human biospecimens, and protected health information in order to develop a comprehensive pediatric biobank in Indiana that can be used by scientists for future unspecified research studies. We are doing this research study because we are trying to find out more about how and why illnesses occur in children.THIS STUDY IS ENROLLING BY INVITATION ONLY - Recruitment to this study will include subjects cared for at a hospital/clinic within the INPC as well as their family members, as detailed in the eligibility criteria. Potential subjects will be identified by the PI or other key-personnel or by self-referral. Informed consent will be obtained from each subject (parent or guardian for pediatric subjects) and assent will be obtained from children who are at least 7 years of age when appropriate. Subjects may also be mailed the study’s informed consent document and assent when appropriate along with a letter explaining why they are being contacted for the study.

Does more than one member of your family have Alzheimer’s disease or serious memory loss?  Your family can be an essential part of Alzheimer's disease research by participating in the NCRAD study. What is this study about?The National Cell Repository for Alzheimer’s Disease (NCRAD) is a research project being conducted at the Indiana University School of Medicine. The goal of NCRAD is to collect blood samples which can be used for research.  The clinical information and biological samples that are collected as part of this study will be used to facilitate studies aimed at locating and identifying factors contributing to dementia and related diseases. In addition, the clinical information and biological samples may also be used to study other diseases.   Our hope is that through the efforts of families with memory loss, we will soon unravel the mystery of conditionslike Alzheimer’s disease. Researchers are actively attempting to understand the genetics of familial conditions having serious memory loss. They are moving rapidly toward this goal, learning more every day. Who can take part?If there are two or more blood- related individuals in your family who are living and have symptoms of memory loss, researchers may be very interested in studying your family. 

What is the purpose of this study?The purpose of this study is to obtain and measure compounds found in exhaled breath samples collected from children with Cystic Fibrosis (CF). These compounds should be different when CF patients are healthy compared to when they have an exacerbation. This information could help the study team develop a non-invasive way to monitor exacerbations in people with CF in the future. THIS STUDY IS ENROLLING BY INVITATION ONLY - Parents and guardians of children with Cystic Fibrosis (CF) who have been hospitalized at Riley Hospital for Children will be identified and approached by the research team about study participation.

What is the purpose of this study?The purpose of the study is to assess the therapeutic benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in improving physical function in End Stage Renal disease (ESRD) patients.  The study is using the drug Empagliflozin, a FDA approved drug for patients with advanced CKD. This study will be investigating the effects Empagliflozin has on physical function, a use that has not been examined in a clinical trial. THIS STUDY IS ENROLLING BY INVITATION ONLY - Recruitment will target non-diabetic dialysis patients. Subjects will be recruited from our outpatient dialysis clinics of the IU Division of Nephrology in accordance with IU recruitment and local clinic policies. Patients may also be recruited from the DaVita, DCI, or Fresenius clinics affiliated with the IU Division of Nephrology. Personnel from the IUSM Division of Nephrology will review medical charts from nephrology clinics for pre-screening to determine potential eligibility. The potential subjects will be contacted by phone or visited by study staff during their outpatient dialysis session. Information about the study may be discussed with interested potential subjects by research personnel by phone, email or in person as preferred by the subject/clinic.